MIGS has no lasting effect on anterior segment parameters

Article

Implantation of the Ex-PRESS miniature device has been found to have no lasting effects on anterior segment parameters, according to recently published data in the Journal of Glaucoma.

Implantation of the Ex-PRESS miniature device has been found to have no lasting effects on anterior segment parameters, according to recently published data in the Journal of Glaucoma.

The study led by Dr Na’ama Hammel (Department of Ophthalmology, Rabin Medical Center, Petah-Tiqva, Israel) analysed 19 eyes of 19 patients to evaluate if the Ex-PRESS miniature glaucoma implant surgery would affect corneal curvature and anterior segment parameters.

The team used the Pentacam rotating Scheimpflug camera (Oculus Inc.) to analyse the eyes preoperatively and then at 1 day, 1 week, 1 month and 3 months postoperatively to determine if there were any changes in parameters. Measurements were taken of the anterior and posterior corneal curvature, anterior and posterior corneal astigmatism, anterior chamber depth (ACD), anterior chamber volume (ACV) and anterior chamber angle before and after surgery.

One day after surgery and at 3 months post-op, the intraocular pressure (IOP) was found to reduce to a statistically significant level. The anterior corneal astigmatism and posterior corneal astigmatism increased, and the ACD and ACV both decreased on the first post-op day. However, at 3 months post-op these changes in anterior segment parameters were not found to be statistically significant.

For more detailed information please view the abstract here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.